SCHEMBL8005772

SCHEMBL8005772

Cn1c(-c2ccccn2)nc(-c2ccc(C(C)(C)O)c(Cl)c2)c1Sc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.61
GRM5 P41594 4/20 0.42
PSD A5PKW4 1/20 0.36
NR1I2 O75469 1/20 0.36
HSD11B1 P28845 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
PPP1CA P62136 1/20 0.36
KDM4E B2RXH2 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
TSHR P16473 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8003243 0.91 FAAH (0.59) FAAHGRM5PSDNR1I2HSD11B1
SCHEMBL8005304 0.87 FAAH (0.65) FAAHGRM5PSDSMN1; SMN2LMNA
SCHEMBL7993064 0.85 FAAH (0.76) FAAHGRM5PSDSMN1; SMN2LMNA
SCHEMBL1304088 0.84 FAAH (0.69) FAAHGRM5PSDSMN1; SMN2LMNA
SCHEMBL8005540 0.83 FAAH (0.60) FAAHGRM5PSDNR1I2HSD11B1
SCHEMBL7992742 0.83 FAAH (0.62) FAAHGRM5NR1I2HSD11B1SMN1; SMN2
SCHEMBL8005184 0.82 FAAH (0.61) FAAHGRM5NR1I2HSD11B1SMN1; SMN2
SCHEMBL8008516 0.82 FAAH (0.71) FAAHGRM5SMN1; SMN2LMNAPOLB
SCHEMBL1302454 0.81 FAAH (0.65) FAAHGRM5NR1I2HSD11B1SMN1; SMN2
SCHEMBL1303133 0.80 FAAH (0.69) FAAHGRM5PSDNR1I2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
WO-2009152025-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HNMT FAAH 1/4885GRM5 786/4885PSD 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.